Precision medicine in type 2 Diabetes: Clinical markers of insulin resistance are associated with altered short- A nd long-term glycemic response to DPP-4 inhibitor therapy

Diabetes Care

Volumn 41, Issue 4, 2018, Pages 705-712

  Dennis, John M ^a   Shields, Beverley M ^a   Hill, Anita V ^a   Knight, Bridget A ^a   McDonald, Timothy J ^a,b   Rodgers, Lauren R ^a   Weedon, Michael N ^a   Henley, William E ^a   Sattar, Naveed ^c   Holman, Rury R ^d   Pearson, Ewan R ^e   Hattersley, Andrew T ^a   Jones, Angus G ^a  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

AGED; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIMARY HEALTH CARE; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 85043583275     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-1827     Document Type: Article

References (41)

1. World Health Organization. Global report on diabetes [Internet], 2016. Available from http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257-eng.pdf. Accessed 19 June 2017
2. National Institute for Health and Care Excellence. Type 2 diabetes in adults: Management. NICE guideline (NG28) [Internet], 2015. Available from https://www.nice.org.uk/guidance/ng28. Accessed 21 June 2017
3. Inzucchi SE, Bergenstal RM, Buse JB, et al.Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149
4. American Diabetes Association. Pharmacologic approaches to glycemic treatment. Sec. 8. In Standards of Medical Care in Diabetes-2017. Diabetes Care 2017;40(Suppl. 1):S64-S74
5. Qaseem A, Barry MJ, Humphrey LL, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetesmellitus: A clinical practice guideline update from the American College of Physicians. Ann Intern Med 2017;166:279-290
6. Florez JC. Precision medicine in diabetes: Is it time Diabetes Care 2016;39:1085-1088
7. Marshall SM. Precision diabetes: A realistic outlook on a promising approach. Diabetologia 2017;60:766-768
8. Hattersley AT, Patel KA. Precision diabetes: Learning from monogenic diabetes. Diabetologia 2017;60:769-777
9. Sattar N. Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance Past, present and future possibilities. Diabet Med 2012;29:5-13
10. Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term trends in antidiabetes drug usage in the U.S.: Real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care 2017;41:69-78
11. Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: A retrospective cohort study. BMJ Open 2016;6:e010210
12. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis. BMJ 2012;344:e1369
13. Bihan H, Ng WL, Magliano DJ, Shaw JE. Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review. Diabetes Res Clin Pract 2016;121:27-34
14. Esposito K, Chiodini P, Maiorino MI, et al. A nomogram to estimate the Hb A1c response to different DPP-4 inhibitors in type 2 diabetes: A systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ Open 2015;5:e005892
15. Jones AG, Mc Donald TJ, Shields BM, et al.; PRIBA Study Group. Markers of b-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care 2016;39:250-257
16. Jones AG, Besser RE, Mc Donald TJ, et al.Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in lateonset, insulin-treated diabetes. Diabet Med 2011;28:1034-1038
17. Besser RE, Ludvigsson J, Jones AG, et al. Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 2011;34:607-609
18. Mc Laughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G.Use ofmetabolicmarkers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802-809
19. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMAmodeling. Diabetes Care 2004;27: 1487-1495
20. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827-836
21. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421
22. Lambert PC, Royston P. Further development of flexible parametricmodels for survival analysis. Stata J 2009;9:265-290
23. Royston P, Lambert PC. Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model. College Station, TX, Stata Press, 2011
24. Jones AG, Lonergan M, Henley WE, Pearson ER, Hattersley AT, Shields BM. Should studies of diabetes treatment stratification correct for baseline Hb A1c PLoS One 2016;11:e0152428
25. Esposito K, Chiodini P, Maiorino MI, Bellastella G, Capuano A, Giugliano D. Glycaemic durabilitywith dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A systematic review and metaanalysis of long-term randomised controlled trials. BMJ Open 2014;4:e005442
26. Ehrenstein V, Nielsen H, Pedersen AB, Johnsen SP, Pedersen L. Clinical epidemiology in the era of big data: New opportunities, familiar challenges. Clin Epidemiol 2017;9:245-250
27. Bujac S, Del Parigi A, Sugg J, et al. Patient characteristics are not associated with clinically important differential response to dapagliflozin: A staged analysis of phase 3 data. Diabetes Ther 2014;5:471-482
28. Zhou K, Donnelly LA, Morris AD, et al. Clinical and genetic determinants of progression of type 2 diabetes: A DIRECT study. Diabetes Care 2014;37: 718-724
29. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998;16:895-906
30. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: A systematic review and meta-analysis. Diabetologia 2013;56:696-708
31. Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: Evidence from randomized clinical trials. Diabetes Metab Res Rev 2011;27:362-372
32. Thompson SG, Higgins JP. How should metaregression analyses be undertaken and interpreted Stat Med 2002;21:1559-1573
33. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI; Anti-Lymphocyte Antibody Induction Therapy Study Group. Individual patient-versus group-level datameta-regressions for the investigation of treatment effect modifiers: Ecological bias rears its ugly head. Stat Med 2002;21:371-387
34. Esposito K, Chiodini P, Capuano A, Maiorino MI, Bellastella G, Giugliano D. Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors: Meta-regression analysis of 78 randomized controlled trials with 20, 053 patients. Endocrine 2014;46:43-51
35. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: A meta-regression analysis. Diabetes Care 2006;29:2137-2139
36. Jamaluddin JL, Huri HZ, Vethakkan SR. Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in type 2 diabetes mellitus. Pharmacogenomics 2016;17:867-881
37. Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulphonylureas in type 2 diabetes. Diabet Med 2006;23:128-133
38. Kang ZF, Deng Y, Zhou Y, et al. Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes. Diabetologia 2013;56:423-433
39. Matikainen N, Bogl LH, Hakkarainen A, et al. GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance. Diabetes Care 2014;37:242-251
40. Alssema M, Rijkelijkhuizen JM, Holst JJ, et al. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. Eur J Endocrinol 2013;169:421-430
41. Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. Cell 2015;163:1079-1094